Indications for worldwide increased norovirus activity associated with emergence of a new variant of genotype II.4, late 2012

J van Beek (janko.van.beek@rivm.nl)1, K Ambert-Balay2, N Botteldoorn³, J S Eden4, J Fonager5, J Hewitt6, N Iritani7, A Kroneman1, H Vennema1, J Vinjé8, P A White4, M Koopmans1, on behalf of NoroNet9

1. National Institute for Public Health and the Environment, Bilthoven, The Netherlands 
2. National Reference Centre for Enteric Viruses, Dijon, France 
3. Scientific Institute of Public Health, Brussels, Belgium 
4. University of New South Wales, Sydney, Australia 
5. Statens Serum Institut, Copenhagen, Denmark 
6. Institute of Environmental Science and Research, Porirua, New Zealand 
7. Osaka City Institute of Public Health and Environmental Sciences, Osaka, Japan 
8. Centers for Disease Control and Prevention, Atlanta, GA, United States 

Citation style for this article:
Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20345

Article submitted on 18 December 2012 / published on 03 January 2013

Globally, surveillance systems showed an increase in norovirus activity in late 2012. Molecular data shared through the NoroNet network suggest that this increase is related to the emergence of a new norovirus genotype II.4 variant, termed Sydney 2012. Healthcare institutions are advised to be prepared for a severe norovirus season.

In the United Kingdom (UK), the Netherlands, and Japan, norovirus (NoV) epidemiological and laboratory surveillance systems show increased levels of NoV activity compared to previous seasons, in late 2012 [1-3]. Similarly, increases have been noted in Australia, France and New Zealand (unpublished data). At this stage, and with the limited surveillance of NoV in most countries, it is difficult to conclude if these increases denote early seasonal activity or truly increased incidence, although for the UK the latter has been suggested. On 29 November, and on 4 and 6 December, ProMed (http://www.promedmail.org/) messages reported a dramatic rise in NoV hospital outbreaks in England, a 64% higher number of confirmed NoV laboratory reports (hospital- and community-acquired) in England and Wales, and NoV-related deaths in elderly in Japan. The first molecular data uploaded to the international molecular surveillance database NoroNet from Australia, France, New Zealand and Japan indicate that this increase is related to the emergence of a new variant of genotype II.4 (GII.4). The first report of this variant was from Australia in March 2012 (personal communication P.A. White, September 2012), and the strain sequence was submitted to GenBank (accession number: JX459908.1). In the United States (US), the variant (named Sydney 2012) was detected in September 2012 in five of 22 (23%) laboratory-confirmed outbreaks, and in November in 37 of 71 (52%) laboratory-confirmed outbreaks (recorded in the US norovirus surveillance network CaliciNet) [4]. In two European countries that have not reported any indications of increased activity, the new variant has been found in outbreaks, two in Belgium (September and December 2012) and one in Denmark (November 2012). Other countries participating in NoroNet have not yet reported the new variant.

NoV is the predominant aetiological viral agent of acute gastroenteritis worldwide and is present throughout the year, but most prevalent in the winter season in temperate climates. In the last decade, strains belonging to NoV GII.4 have been responsible for the majority of outbreaks, as well as community cases of acute gastroenteritis. It has been suggested that hospitalisation and deaths occur more frequently during peak seasons associated with new NoV GII.4 variants [5-7]. Since 1995, new epidemic variants of GII.4 have emerged every two to three years, with population immunity and genetic drift as major evolutionary driving forces [8]. Emergence of new variants has been associated with increased NoV activity early in the season [9-11]. The newly found NoV GII.4 Sydney 2012 variant has evolved from previous NoV GII.4 variants (Figure 1) and will be described in detail elsewhere. Briefly, the NoV GII.4 Sydney 2012 variant has a common ancestor with the dominant NoV GII.4 variants Apeldoorn_2007 and NewOrleans_2009, but is phylogenetically distinct. Amino acid changes are seen in the main epitopes located at the P2 domain, consistent with observations from prior epidemics. This may have led to an escape to
With the early signs of a severe NoV season, health-care institutions are advised to be prepared for NoV introductions. Outbreak management measures, like stringent hygiene measures and quarantine of infected cases, can help to reduce the size of outbreaks [14,15].

References


